JP2012509678A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509678A5 JP2012509678A5 JP2011537890A JP2011537890A JP2012509678A5 JP 2012509678 A5 JP2012509678 A5 JP 2012509678A5 JP 2011537890 A JP2011537890 A JP 2011537890A JP 2011537890 A JP2011537890 A JP 2011537890A JP 2012509678 A5 JP2012509678 A5 JP 2012509678A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- polynucleotide
- vector
- promoter
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 23
- 102000039446 nucleic acids Human genes 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 22
- 108091033319 polynucleotide Proteins 0.000 claims 19
- 102000040430 polynucleotide Human genes 0.000 claims 19
- 239000002157 polynucleotide Substances 0.000 claims 19
- 239000002773 nucleotide Substances 0.000 claims 17
- 125000003729 nucleotide group Chemical group 0.000 claims 17
- 239000013598 vector Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 7
- 108091081024 Start codon Proteins 0.000 claims 4
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241000700618 Vaccinia virus Species 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 210000003754 fetus Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000002510 keratinocyte Anatomy 0.000 claims 1
- 210000003292 kidney cell Anatomy 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000005257 nucleotidylation Effects 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08020617 | 2008-11-27 | ||
| EP08020617.0 | 2008-11-27 | ||
| PCT/EP2009/008459 WO2010060632A1 (en) | 2008-11-27 | 2009-11-27 | Promoters for recombinant viral expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015230172A Division JP6291467B2 (ja) | 2008-11-27 | 2015-11-26 | 組換えウイルス発現のためのプロモーター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012509678A JP2012509678A (ja) | 2012-04-26 |
| JP2012509678A5 true JP2012509678A5 (enExample) | 2012-11-29 |
Family
ID=40419479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537890A Pending JP2012509678A (ja) | 2008-11-27 | 2009-11-27 | 組換えウイルス発現のためのプロモーター |
| JP2015230172A Active JP6291467B2 (ja) | 2008-11-27 | 2015-11-26 | 組換えウイルス発現のためのプロモーター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015230172A Active JP6291467B2 (ja) | 2008-11-27 | 2015-11-26 | 組換えウイルス発現のためのプロモーター |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8772023B2 (enExample) |
| EP (1) | EP2367944B1 (enExample) |
| JP (2) | JP2012509678A (enExample) |
| AU (1) | AU2009319336B2 (enExample) |
| CA (1) | CA2741724C (enExample) |
| DK (1) | DK2367944T3 (enExample) |
| NZ (1) | NZ592082A (enExample) |
| WO (1) | WO2010060632A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010057650A1 (en) | 2008-11-21 | 2010-05-27 | Bavarian Nordic A/S | Vector comprising multiple homologous nucleotide sequences |
| DK2788021T3 (en) | 2011-12-09 | 2017-04-10 | Bavarian Nordic As | POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| WO2014063832A1 (en) | 2012-10-28 | 2014-05-01 | Bavarian Nordig A/S | Pr13.5 promoter for robust t-cell and antibody responses |
| KR20160140075A (ko) | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| WO2016202828A1 (en) * | 2015-06-15 | 2016-12-22 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| WO2017129765A1 (en) | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
| EP3518964A2 (en) | 2016-09-28 | 2019-08-07 | Bavarian Nordic A/S | Compositions and methods for enhancing the stability of transgenes in poxviruses |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| EP3562946B1 (en) | 2016-12-28 | 2021-11-24 | Transgene SA | Oncolytic viruses and therapeutic molecules |
| BR112019026126A2 (pt) | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| JP7202362B2 (ja) | 2017-08-24 | 2023-01-11 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法 |
| MX2020006471A (es) | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| EP3860641A1 (en) | 2018-10-05 | 2021-08-11 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
| CN113056284A (zh) | 2018-11-20 | 2021-06-29 | 巴法里安诺迪克有限公司 | 通过肿瘤内和/或静脉内施用编码4-1bbl(cd137l)和/或cd40l的重组mva治疗癌症的疗法 |
| CN114867491B (zh) | 2019-11-20 | 2025-08-15 | 巴法里安诺迪克有限公司 | 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒 |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| EP4452306A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| EP4452305A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| US20250387463A1 (en) | 2022-06-29 | 2025-12-25 | Bavarian Nordic A/S | Recombinant Modified saRNA (VRP) and Vaccinia Virus Ankara (MVA) Prime-Boost Regimen |
| WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
| JP2026502453A (ja) | 2023-01-12 | 2026-01-23 | バヴァリアン・ノルディック・アクティーゼルスカブ | がんワクチンのための組み換え改変ｓａＲＮＡ（ＶＲＰ） |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0568539A4 (en) * | 1990-11-06 | 1994-07-06 | Childrens Medical Center | Soluble mannose receptor peptides |
| US7314974B2 (en) * | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| US7312202B2 (en) * | 2003-02-18 | 2007-12-25 | Board Of Regents, The University Of Texas System | Rationally designed and chemically synthesized promoter for genetic vaccine and gene therapy |
| DE602004009743T2 (de) * | 2003-11-24 | 2008-08-28 | Bavarian Nordic A/S | Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara |
| US10111946B2 (en) * | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
-
2009
- 2009-11-27 WO PCT/EP2009/008459 patent/WO2010060632A1/en not_active Ceased
- 2009-11-27 AU AU2009319336A patent/AU2009319336B2/en active Active
- 2009-11-27 DK DK09764186.4T patent/DK2367944T3/en active
- 2009-11-27 JP JP2011537890A patent/JP2012509678A/ja active Pending
- 2009-11-27 US US13/131,586 patent/US8772023B2/en active Active
- 2009-11-27 EP EP09764186.4A patent/EP2367944B1/en active Active
- 2009-11-27 CA CA2741724A patent/CA2741724C/en active Active
- 2009-11-27 NZ NZ592082A patent/NZ592082A/xx unknown
-
2014
- 2014-06-03 US US14/295,275 patent/US20140342403A1/en not_active Abandoned
-
2015
- 2015-11-26 JP JP2015230172A patent/JP6291467B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023532663A5 (enExample) | ||
| Vrati et al. | Unique genome arrangement of an ovine adenovirus: identification of new proteins and proteinase cleavage sites | |
| LEE et al. | Difference in the meq gene between oncogenic and attenuated strains of Marek’s disease virus serotype 1 | |
| Smith et al. | Vaccinia virus encodes a thymidylate kinase gene: sequence and transcriptional mapping | |
| JP2013507935A5 (enExample) | ||
| KR102433709B1 (ko) | 재조합 ｏｒｆ 바이러스 벡터 | |
| JP2012509678A (ja) | 組換えウイルス発現のためのプロモーター | |
| JP2012515557A5 (enExample) | ||
| JP2024535145A5 (enExample) | ||
| WO2011095760A1 (en) | Bunyavirus vaccine | |
| CN103173455B (zh) | 一种具有抗新城疫病毒活性的鹅源基因rig-i及其应用 | |
| WO1992012240A1 (en) | Interferon sensitive recombinant poxvirus vaccine | |
| CA2909225C (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
| EP3158060B1 (en) | Method for rapid generation of an infectious rna virus | |
| JP2011523642A5 (enExample) | ||
| CN102321661A (zh) | 一种真核表达重组质粒及其构建方法与稳定表达该质粒的Vero细胞系 | |
| JP2012532933A5 (enExample) | ||
| US20080267992A1 (en) | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine | |
| CN108018267A (zh) | 一种靶向表观基因调控抗乙型肝炎病毒分子HBx1C及其应用 | |
| JP6386448B2 (ja) | ブタインターフェロンアルファ及びブタインターフェロンガンマを同時に発現する組換えアデノウィルス | |
| US5374558A (en) | Fowlpox virus promoter | |
| CN101215575A (zh) | 兔病毒性出血症病毒衣壳蛋白基因重组腺病毒及疫苗 | |
| CN104593336A (zh) | 猪繁殖与呼吸综合征嵌合病毒RvHBJX及其应用 | |
| Kleiboeker | Identification and sequence analysis of the E1 genomic region of a porcine adenovirus | |
| JP2024512722A5 (enExample) |